X Linked Adrenoleukodystrophy Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, X Linked Adrenoleukodystrophy pipeline constitutes 3+ key companies continuously working towards developing 3+ X Linked Adrenoleukodystrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

X Linked Adrenoleukodystrophy Overview
X Linked Adrenoleukodystrophy (X-ALD) is a genetic disease that affects the nervous system and the adrenal glands (small glands located on top of each kidney). People with this disease often have progressive loss of the fatty covering (myelin) that surrounds the nerves in the brain and spinal cord.

"X Linked Adrenoleukodystrophy Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the X Linked Adrenoleukodystrophy Market.

The X Linked Adrenoleukodystrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the X Linked Adrenoleukodystrophy Pipeline Report: https://www.delveinsight.com/report-store/x-linked-adrenoleukodystrophy-x-ald-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel X Linked Adrenoleukodystrophy treatment therapies with a considerable amount of success over the years. X Linked Adrenoleukodystrophy Key players such as - Minoryx Therapeutics, Poxel SA, SwanBio Therapeutics, Viking Therapeutics, and others, are developing therapies for the X Linked Adrenoleukodystrophy treatment
• X Linked Adrenoleukodystrophy Emerging therapies such as - ABX-002, VK0214, SBT101, PXL065, PXL770, Leriglitazone (MIN102), and others are expected to have a significant impact on the X Linked Adrenoleukodystrophy market in the coming years.
• In May 2022, Minoryx Therapeutics announced that it had closed a €51 million financing, including Series C equity financing and complementary bank debt. Minoryx will use the funding to finance the marketing authorization application (MAA) and launch preparations of its drug candidate leriglita zone for adult male X-ALD patients with adrenomyeloneuropathy (AMN) in the EU.
• In November 2021, Minoryx Therapeutics announced that the additional data of its Phase 2/3 ADVANCE clinical trial had been presented in a poster presentation at the 146th Annual Meeting of the American Neurological Association (ANA) 2021.

Route of Administration
X Linked Adrenoleukodystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type
Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

X Linked Adrenoleukodystrophy Pipeline Therapeutics Assessment
• X Linked Adrenoleukodystrophy Assessment by Product Type
• X Linked Adrenoleukodystrophy By Stage and Product Type
• X Linked Adrenoleukodystrophy Assessment by Route of Administration
• X Linked Adrenoleukodystrophy By Stage and Route of Administration
• X Linked Adrenoleukodystrophy Assessment by Molecule Type
• X Linked Adrenoleukodystrophy by Stage and Molecule Type

DelveInsight's X Linked Adrenoleukodystrophy Report covers around 3+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the X Linked Adrenoleukodystrophy Therapeutics Market include:
Key companies developing therapies for X Linked Adrenoleukodystrophy are - Autobahn Therapeutics, Minoryx Therapeutics, Poxel, Orpheris, Applied Genetic Technologies Corporation, NEURALGENE, and others.

Emerging X Linked Adrenoleukodystrophy Drugs Under Different Phases of Clinical Development Include:
• ABX-002: Autobahn Therapeutics
• VK0214: Viking Therapeutics
• SBT101: SwanBio Therapeutics
• PXL065: Poxel SA
• PXL770: Poxel SA
• Leriglitazone (MIN102): Minoryx Therapeutics

Get a Free Sample PDF Report to know more about X Linked Adrenoleukodystrophy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/x-linked-adrenoleukodystrophy-x-ald-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

X Linked Adrenoleukodystrophy Pipeline Analysis:
The X Linked Adrenoleukodystrophy pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of X Linked Adrenoleukodystrophy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for X Linked Adrenoleukodystrophy Treatment.
• X Linked Adrenoleukodystrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• X Linked Adrenoleukodystrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the X Linked Adrenoleukodystrophy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further X Linked Adrenoleukodystrophy product details are provided in the report. Download the X Linked Adrenoleukodystrophy pipeline report to learn more about the emerging X Linked Adrenoleukodystrophy therapies at:
https://www.delveinsight.com/report-store/x-linked-adrenoleukodystrophy-x-ald-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

X Linked Adrenoleukodystrophy Pipeline Market Drivers
• Increasing awareness towards genetic diseases coupled with genetic counselling
• Rise in number of R&D activities

X Linked Adrenoleukodystrophy Pipeline Market Barriers
• High cost of the treatment
• Side effects associated with the treatment

Scope of X Linked Adrenoleukodystrophy Pipeline Drug Insight
• Coverage: Global
• Key X Linked Adrenoleukodystrophy Companies:
• Minoryx Therapeutics, Poxel SA, SwanBio Therapeutics, Viking Therapeutics, and others
• Key X Linked Adrenoleukodystrophy Therapies: ABX-002, VK0214, SBT101, PXL065, PXL770, Leriglitazone (MIN102), and others
• X Linked Adrenoleukodystrophy Therapeutic Assessment: X Linked Adrenoleukodystrophy current marketed and X Linked Adrenoleukodystrophy emerging therapies
• X Linked Adrenoleukodystrophy Market Dynamics: X Linked Adrenoleukodystrophy market drivers and X Linked Adrenoleukodystrophy market barriers

Request for Sample PDF Report for X Linked Adrenoleukodystrophy Pipeline Assessment and clinical trials-
https://www.delveinsight.com/report-store/x-linked-adrenoleukodystrophy-x-ald-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 X Linked Adrenoleukodystrophy Report Introduction
2 X Linked Adrenoleukodystrophy Executive Summary
3 X Linked Adrenoleukodystrophy Overview
4 X Linked Adrenoleukodystrophy- Analytical Perspective In-depth Commercial Assessment
5 X Linked Adrenoleukodystrophy Pipeline Therapeutics
6 X Linked Adrenoleukodystrophy Late Stage Products (Phase II/III)
7 X Linked Adrenoleukodystrophy Mid Stage Products (Phase II)
8 X Linked Adrenoleukodystrophy Early Stage Products (Phase I)
9 X Linked Adrenoleukodystrophy Preclinical Stage Products
10 X Linked Adrenoleukodystrophy Therapeutics Assessment
11 X Linked Adrenoleukodystrophy Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 X Linked Adrenoleukodystrophy Key Companies
14 X Linked Adrenoleukodystrophy Key Products
15 X Linked Adrenoleukodystrophy Unmet Needs
16 X Linked Adrenoleukodystrophy Market Drivers and Barriers
17 X Linked Adrenoleukodystrophy Future Perspectives and Conclusion
18 X Linked Adrenoleukodystrophy Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about X Linked Adrenoleukodystrophy drugs and therapies- https://www.delveinsight.com/report-store/x-linked-adrenoleukodystrophy-x-ald-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Related Reports By DelveInsight -

Hypertrophic Scar Market
https://www.delveinsight.com/report-store/hypertrophic-scar-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Hypertrophic Scar Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypertrophic Scar, historical and forecasted epidemiology as well as the Hypertrophic Scar market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Lung Fibrosis Market https://www.delveinsight.com/report-store/lung-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Lung Fibrosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Lung Fibrosis, historical and forecasted epidemiology as well as the Lung Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Anterior Uveitis Market https://www.delveinsight.com/report-store/anterior-uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Anterior Uveitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Anterior Uveitis, historical and forecasted epidemiology as well as the Anterior Uveitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

22q11.2 deletion syndrome Market https://www.delveinsight.com/report-store/22q112-deletion-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "22q11.2 Deletion Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the 22q11.2 Deletion Syndrome, historical and forecasted epidemiology as well as the 22q11.2 Deletion Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

X-Linked Retinitis Pigmentosa (XLRP) Market https://www.delveinsight.com/report-store/x-linked-retinitis-pigmentosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "X-Linked Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the X-Linked Retinitis Pigmentosa (XLRP), historical and forecasted epidemiology as well as the X-Linked Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Recent Blog's By DelveInsight:

• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry
https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:

Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com/consulting

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.